ARVN: Arvinas, Inc.
Performance
ARVN -36.41%
Watchlist
Select an item
Summary
ARVN at a glance
ARVN returned -36.41% over the past year and -40.54% a year over five years. Its worst drop in that year was -53.65%, smaller than 18% of stocks on Redstone, and its Sharpe ratio of -0.58 beats 10% of stocks on Redstone. It pays no dividends.
Current Drawdown
-51.12%
Rolling Volatility
73.73%
Actions
Metrics
Risk Indicators
Alpha-46.95%
Beta1.40x
Sharpe-0.58
Sortino-0.82
Omega0.90
Calmar-0.68
Martin-1.07
Profile
About ARVN
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $443M
- Listed
- Sep 2018
- Employees
- 246
- Headquarters
- New Haven, CT
- Website
- arvinas.com
Comparisons